pure bioscience - PURE

PURE

Close Chg Chg %
0.07 0.02 28.33%

Closed Market

0.08

+0.02 (28.33%)

Volume: 24.81K

Last Updated:

Jul 18, 2025, 3:31 PM EDT

Company Overview: pure bioscience - PURE

PURE Key Data

Open

$0.07

Day Range

0.07 - 0.08

52 Week Range

0.05 - 0.21

Market Cap

$7.83M

Shares Outstanding

111.89M

Public Float

65.73M

Beta

0.20

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$0.03

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

40.79K

 

PURE Performance

1 Week
 
1.19%
 
1 Month
 
-21.57%
 
3 Months
 
36.52%
 
1 Year
 
17.64%
 
5 Years
 
-93.91%
 

PURE Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About pure bioscience - PURE

PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in El Cajon, CA.

PURE At a Glance

PURE Bioscience, Inc.
771 Jamacha Road
El Cajon, California 92019
Phone 1-619-596-8600 Revenue 1.96M
Industry Chemicals: Major Diversified Net Income -3,350,000.00
Sector Process Industries 2024 Sales Growth 4.582%
Fiscal Year-end 07 / 2025 Employees 12
View SEC Filings

PURE Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 4.547
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -3.839
Enterprise Value to Sales 5.833
Total Debt to Enterprise Value 0.258

PURE Efficiency

Revenue/Employee 163,583.333
Income Per Employee -279,166.667
Receivables Turnover 6.587
Total Asset Turnover 1.485

PURE Liquidity

Current Ratio 1.098
Quick Ratio 1.022
Cash Ratio 0.578

PURE Profitability

Gross Margin 58.686
Operating Margin -159.501
Pretax Margin -170.657
Net Margin -170.657
Return on Assets -253.50
Return on Equity N/A
Return on Total Capital -3,941.176
Return on Invested Capital -486.212

PURE Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 3,469.412
Total Debt to Total Assets 360.513
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 3,469.412
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pure Bioscience - PURE

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
3.93M 1.85M 1.88M 1.96M
Sales Growth
-43.23% -52.81% +1.30% +4.58%
Cost of Goods Sold (COGS) incl D&A
1.85M 853.00K 906.00K 811.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
172.00K 213.00K 117.00K 148.00K
Depreciation
97.00K 146.00K 117.00K 148.00K
Amortization of Intangibles
- - 75.00K 67.00K
-
COGS Growth
-36.05% -53.94% +6.21% -10.49%
Gross Income
2.08M 1.00M 971.00K 1.15M
Gross Income Growth
-48.40% -51.81% -2.90% +18.64%
Gross Profit Margin
+52.84% +53.97% +51.73% +58.69%
2021 2022 2023 2024 5-year trend
SG&A Expense
4.39M 4.42M 4.60M 4.28M
Research & Development
339.00K 319.00K 297.00K 302.00K
Other SG&A
4.05M 4.11M 4.30M 3.98M
SGA Growth
+9.19% +0.89% +3.93% -6.87%
Other Operating Expense
- - - -
-
Unusual Expense
- 60.00K 315.00K 60.00K
EBIT after Unusual Expense
(2.31M) (3.48M) (3.94M) (3.19M)
Non Operating Income/Expense
- (4.00K) (4.00K) (4.00K)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.00K 6.00K 14.00K 155.00K
Interest Expense Growth
-20.00% +50.00% +133.33% +1,007.14%
Gross Interest Expense
4.00K 6.00K 14.00K 155.00K
Interest Capitalized
- - - -
-
Pretax Income
(2.32M) (3.49M) (3.96M) (3.35M)
Pretax Income Growth
-58,075.00% -50.54% -13.46% +15.43%
Pretax Margin
-59.05% -188.40% -211.03% -170.66%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(2.32M) (3.49M) (3.96M) (3.35M)
Minority Interest Expense
- - - -
-
Net Income
(2.32M) (3.49M) (3.96M) (3.35M)
Net Income Growth
-58,075.00% -50.54% -13.46% +15.43%
Net Margin Growth
-59.05% -188.40% -211.03% -170.66%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(2.32M) (3.49M) (3.96M) (3.35M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(2.32M) (3.49M) (3.96M) (3.35M)
EPS (Basic)
-0.0266 -0.0393 -0.0356 -0.03
EPS (Basic) Growth
- -47.74% +9.41% +15.73%
Basic Shares Outstanding
87.17M 88.84M 111.40M 111.86M
EPS (Diluted)
-0.0266 -0.0393 -0.0356 -0.03
EPS (Diluted) Growth
- -47.74% +9.41% +15.73%
Diluted Shares Outstanding
87.17M 88.84M 111.40M 111.86M
EBITDA
(2.14M) (3.21M) (3.51M) (2.98M)
EBITDA Growth
-1,191.33% -50.16% -9.31% +15.04%
EBITDA Margin
-54.47% -173.34% -187.05% -151.96%

Insider Actions for Pure Bioscience - PURE

Date Name Shares Transaction Value
Aug 23, 2024 Robert F. Bartlett CEO and President; Director 155,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Robert F. Bartlett CEO and President; Director 500,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Mark S. Elliott Vice President, Finance 155,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Tom Myers Exec VP, Tech & Development 155,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Tom Y. Lee Director 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Ivan Chen Director 150,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 David M. Rendall Director 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Bernard Blotner Director 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 23, 2024 Darin Zehr Director 125,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Pure Bioscience in the News